Quarterly ResultMay 6, 2026, 06:13 AM
Smith+Nephew Q1 Revenue $1.50B; New $500M Buyback Announced
AI Summary
Smith+Nephew reported first-quarter 2026 revenue of $1,501 million, reflecting 3.1% underlying growth, in line with expectations. The company announced a new $500 million share buyback, demonstrating confidence in its 2026 performance and strong financial position. Full-year 2026 guidance remains unchanged, projecting around 6% underlying revenue growth and 8% trading profit growth. Performance was driven by strong Sports Medicine growth, offsetting anticipated softness in US Knee Implants, and the company also announced a new President for Orthopaedics.
Key Highlights
- New $500 million share buyback announced, to be completed within 12 months.
- Q1 2026 revenue $1,501 million, with underlying revenue growth of 3.1%.
- Full year 2026 guidance for underlying revenue growth around 6% remains unchanged.
- Full year 2026 trading profit growth around 8% (approx. $1.3 billion) unchanged.
- Sports Medicine & ENT revenue $491 million, with underlying growth of 6.7%.
- Orthopaedics revenue $599 million, with underlying growth of 0.8%, including a 10.3% decline in US Knee Implants.
- Nathan Folkert appointed President, Orthopaedics, replacing Craig Gaffin.